This week I had a chance to interview Dr. Vivian Fonseca on the use of GLP-1 agonists, and he shared his thoughts on why these medications are a logical choice. He also gave us a little information on a study using GLP-1 agonists with insulin, and why he thinks the FDA should approve the combination.

Our GLP-1 Case Study this week targets a 25-year-old Hispanic woman with a 5-year history of type 2 diabetes, who has not been able to get her A1c under control, and Louis Kuritzky, MD, Clinical Assistant Professor, University of Florida, has a short interactive video on the potential for tissue damage before and after diagnosis of diabetes, and the protective benefits of early and effective intervention.

Examine the progressive nature of diabetes from a clinical perspective, including the potential for tissue damage both before and after diagnosis, and the protective benefits of early and effective intervention. Presented by Louis Kuritzky, MD, Clinical Assistant Professor, Department of Community Health and Family Medicine, University of Florida, Gainesville....

A 25-year-old Hispanic woman with a 5-year history of type 2 diabetes presents for a routine follow-up visit. Despite education, she has had difficulty making diet and lifestyle modifications and currently has a BMI of 45 kg/m²....

Exenatide, a glucagon-like peptide-1 (GLP-1) agonist was associated with significant weight loss in obese women who were not diabetic, according to research....

TransPharma Medical, Ltd., announced the successful completion of a Phase 1a trial of ViaDerm-GLP1 agonist which is being developed for the treatment of Type 2 diabetes....

Published results from the LEAD 6 extension study showed the efficacy and safety of switching from exenatide, taken twice a day, to once-daily Victoza. Results show...